| Description: |
Introduction. The COVID-19 pandemic causes an increase in cardiovascular pathologies, such as chronic heart failure (CHF) in the post-Covid period. The changes may be associated with inflammation, immune dysregulation, and hyperglycemia. An important task for healthcare is to study the effect of carbohydrate metabolism disorders on CHF in patients after COVID-19. Aim: To study the impact of carbohydrate metabolism disorders on the prognosis of CHF in postCOVID-19 patients.Material and Methods. A retrospective analysis of patients of the Tyumen Cardiology Research Center, Tomsk NMRC (TCRC) (n = 350) was carried out. The patients had COVID-19 in 2020–2021 and were observed at the TСRC from April 10, 2020 to July 11, 2022. The study included 116 patients. Patients were divided into 2 groups: with CHF (n = 63) and without CHF (n = 53). Verification of CHF was carried out according to the clinical guidelines "Chronic Heart Failure" (2020), approved by the Ministry of Health of the Russian Federation. A comprehensive examination (cardiologist examination, laboratory and instrumental examination) of the participants was performed 3 and 12 months after suffering lung damage from COVID-19. Results. Patients with CHF in the post-Covid showed statistically significantly higher levels of HbA1c (p = 0.01), LDL-C (p < 0.01), IL-8 (p < 0.01) compared to patients without CHF. According to the results of ROC analysis, HbA1c predicts the development of CHF in the post-Covid. Area under the ROC is 0.823±0.061 with 95% CI: 0.704-0.42 (p = 0.001). The threshold value for HbA1c is 5.95%. Statistically significant logistic regression model for the development of CHF within a year after COVID-19 was obtained. Model indicators: HbA1c, LDL-C, IL-8, presence of ischemic heart disease. ROC analysis of the model AUC = 0.91 ± 0.04 (p < 0.001). Sensitivity – 90.1%, specificity – 79.3%.Conclusion. HbA1c, LDL-C and IL-8 have a high prognostic significance in the development of CHF in postCOVID-19 patients. A statistically significant ... |
| Relation: |
https://www.sibjcem.ru/jour/article/view/2734/1078; Alvarez-Garcia J., Jaladanki S., Rivas-Lasarte M., Cagliostro M., Gupta A., Joshi A. et al. New heart failure diagnoses among patients hospitalized for COVID-19. J. Am. Coll. Cardiol. 2021;(77):2260–2262. https://doi.org/10.1016/j.jacc.2021.03.006; Масалкина О.В., Козиолова Н.А., Сюзева Н.М. Распространенность и характеристика впервые выявленной хронической сердечной недостаточности у больных с одышкой, перенесших новую коронавирусную инфекцию. Российский кардиологический журнал. 2023;28(3):5385. https://doi.org/10.15829/1560-4071-2023-5385; Карасева А.А., Худякова А.Д., Гарбузова Е.В., Рагино Ю.И., Логвиненко И.И. Степени тяжести постковидного синдрома: систематический обзор. Архивъ внутренней медицины. 2023;13(6):422– 435. https://doi.org/10.20514/2226-6704-2023-13-6-422-435; Man D.E., Andor M., Buda V., Kundnani N.R., Duda-Seiman D.M., Craciun L.M. et al. Insulin Resistance in Long COVID-19 Syndrome. J. Pers. Med. 2024;14(9):911. https://doi.org/10.3390/jpm14090911; Tandon P., Abrams N.D., Avula L.R., Carrick D.M., Chander P., Divi R.L. et al. Unraveling links between chronic inflammation and long COVID: Workshop Report. J. Immunol. 2024;(212):505–512. https://doi.org/10.4049/jimmunol.2300804; Zadeh F.H., Wilson D.R., Agrawal D.K. Long COVID: complications, underlying mechanisms, and treatment strategies. Arch. Microbiol. Immunol. 2023;(7):36–61. PMID: 37388279.; Goel V., Raizada A., Aggarwal A., Madhu S.V., Kar R., Agrawal A. et al. Long-term persistence of COVID-induced hyperglycemia: a cohort study. Am. J. Trop. Med. Hyg. 2024;(110):512–517. https://doi.org/10.4269/ajtmh.22-0695; Olumuyide E., Agwuegbo C.C., Ahmed E.N. Exploring the heart failure connection in long COVID patients: a narrative review. Cureus. 2024;16(4):58694. https://doi.org/10.7759/cureus.58694; La Roi-Teeuw H.M., van Smeden M., Geersing G.J., Klungel O.H., Rutten F.H., Souverein P.C. et al. Incidence and individual risk prediction of post-COVID-19 cardiovascular disease in the general population: a multivariable prediction model development and validation study. Eur. Heart J. Open. 2023;3(6):101. https://doi.org/10.1093/ehjopen/oead101; Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3; Conte C., Cipponeri E., Roden M. Diabetes mellitus, energy metabolism, and COVID-19. Endocr. Rev. 2024;(45):281–308. https://doi.org/10.1210/endrev/bnad032; Wong N.D., Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat. Rev. Cardiol. 2023;(20):685–695. https://doi.org/10.1038/s41569-023-00877-z; Menezes D.C., Lima P.D.L., Lima I.C., Uesugi J.H.E., Vasconcelos P.F.D.C., Quaresma J.A.S. et al. Metabolic profile of patients with long COVID: a cross-sectional study. Nutrients. 2023;(15):1197. https://doi.org/10.3390/nu15051197; Durrington P. Blood lipids after COVID-19 infection. Lancet Diabetes Endocrinol. 2023;11(2):68–69. https://doi.org/10.1016/S22138587(22)00389-8; Liu T., Kang H. The risk factors for long term cardiovascular symptoms in patients after coronavirus disease 2019 infection. Ann. Med. 2024;56(1):2407065. https://doi.org/10.1080/07853890.2024.2407065; Tilikete C., Zamali I., Meddeb Z., Kharroubi G., Marzouki S., Dhaouadi T. et al. Exploring the landscape of symptom-specific inflammatory cytokines in post-COVID syndrome patients. BMC Infect. Dis. 2024;24:1337. https://doi.org/10.1186/s12879-024-10222-5; Sharma A., Garcia G. Jr., Wang Y., Plummer J.T., Morizono K., Arumugaswami V. et al. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Rep. Med. 2020;1(4):100052. https://doi.org/10.1016/j.xcrm.2020.100052; Sukosd E.I., Kundnani N.R., Moise H.E., Stelian M., Bodea O.M., Minodoara A. Quality of life of chronic heart failure patients during and after COVID-19: Observational study using EuroQoL-visual analogue scales. Med. Sci. Monit. 2024;(30):943301. https://doi.org/10.12659/MSM.943301; Schultheiß C., Willscher E., Paschold L., Gottschick C., Klee B., Bosurgi L. et al. Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19. J. Med. Virol. 2023;95(1):28364. https://doi.org/10.1002/jmv.28364; https://www.sibjcem.ru/jour/article/view/2734 |
| Rights: |
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы рукописи соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License (CC-BY) которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение в институтском хранилище, публикацию в книге), со ссылкой на оригинальную публикацию в этом журнале.Авторы имеют право размещать работу в сети Интернет (например, в институтском хранилище или на персональном сайте) до и во время процесса рассмотрения рукописи данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |